Member Info for ConsDoms

I was always happy to trust Dr S (I still trust the science and didn’t think I’d be topping up post lift but I have), but I do think he owes shareholders some clarification of recent events. Somebody raised the question earlier - were HEMO in discussion with potential JV partners? and did Vlad think their offer/ valuation was inadequate given what he sees as the potential? What was the basis for indicating trials would commence 2023 and why has that time not been achieved?

Well said Hik. possibly post of the day🥇

7V. Indeed - what exactly is gong on? Why has Vlad been so quiet when now, of all times, he has significant legitimate progress to shout about.

This is what I am thinking / hoping Haywain. Perhaps HEMO need a little cash injection to trial say 3 patients, following which they can hopefully demonstrate HEMO CAR T works and clears the recognized safety / efficacy markers. Then what will the value be...

Yawn

Comments / observations only made in the context of CAR T as that was the treatment under discussion

Thank you Stu😉.

many seem to suggest / infer (or even state) HEMO need to find millions and millions. But do they? The may get a helping hand. Who knows🤷🏻‍♂️.

I’m guessing by your posts you have a little stake here.

GL.

Cons

Hi Stu. ''The risks in this specific AML clinical trial field are greater now than when Hemo’ first set upon the path & the costs associated are greater''. Do you have an idea of what the clinical costs are, what are they greater than? Couldnt there be a scenario whereby, after 2-3 patients respond positively, others (not HEMO) bear the cost from that point onwards? How do you see Ph1 unfolding? thanks

Are you blaming Tilly for the Russian invasion of Ukraine then? EUA went from sub 1p to 40p - some people made a lot of money

Only 3bn

Name one

Yes. and it peaked at ~6.5? intraday on the 9th Feb. but its mcap has only really been fluctuating between 30-£50m - nothing in the grand scheme of things. massively de-risked now and still from an extraordinary low base. just my view

''The net proceeds from the Placing will be used to facilitate progression of the Company's Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML"). Specifically, and as outlined by the Company in its announcement of 15 November 2023, this fundraise will help the Company to accelerate the completion of work set out in the plan presented and agreed to by the FDA and to re-submit the Investigational New Drug ("IND") application for the HEMO-CAR-T product. The funds will also enable the Company, in view of recently announced successes, to provide modest additional resources to the development of its CBR platform''

to get to where we are now?

In my 4th year also. And I had expected this would be sitting at ~10p after hold lift. But the last two RNS show phenomenal progress - so I do think we will see what we believe is the true value emerge very soon (I cannot see why not). GLA

I think clarity on trial funding will move this Micky. And that funding doesn't necessarily need to be significant - if as JHFH indicates, HEMO present positive results in the first two to three patients, surely at that point this will rise dramatically (if not before)

Https://www.standard.co.uk/news/world/what-is-disease-x-vaccine-pandemic-wef-davos-b1099041.html

What are you reading India? Dr S just says work and pressure high

Brilliant clarity Haywain. thank you

IG. nobody is treating / targeting the protein HEMO are for AML - it is unique

Well said Chris. I firmly believe this is now just the start - this is the firm foundation for what will be a very interesting journey. the true value will out and hopefully many lives will be saved. many thanks to those who have brought genuine technical insight here over the last few years, particularly you JHFH, pour yourself a nice glass of something tonight. best wishes. GLA